HOOKIPA Pharma, Inc. (HOOK)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about HOOKIPA Pharma, Inc. (HOOK)
Company Performance

Current Price

as of Oct 16, 2024

$3.90

P/E Ratio

N/A

Market Cap

$37.65M

Description

HOOKIPA Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in developing pharmaceutical products to prevent and cure infectious diseases and cancer. The firm also focuses on immunotherapeutics based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. The company was founded by Rolf M. Zinkernagel, Andreas Bergthaler, Lukas Flatz, and Daniel D. Pinschewer in 2011 and is headquartered in New York, NY.

Metrics

Overview

  • HQNew York, NY
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerHOOK
  • Price$3.9+6.85%

Trading Information

  • Market Cap$37.65M
  • Float64.39%
  • Average Daily Volume (1m)30,137
  • Average Daily Volume (3m)28,023
  • EPS-$4.61

Company

  • Revenue$52.16M
  • Rev Growth (1yr)-51.85%
  • Net Income-$19.10M
  • Gross Margin44.65%
  • EBITDA Margin-1,681.40%
  • EBITDA-$21.69M
  • EV$1.95M
  • EV/Revenue0.04
  • P/EN/A
  • P/S0.94
  • P/B0.45
Documents
SEC Filings
8-K (2024-08-30)
8-K (2024-08-08)
8-K (2024-07-26)
8-K (2024-07-10)
8-K (2024-06-18)
8-K (2024-06-04)
8-K (2024-05-23)
8-K (2024-05-09)
8-K (2024-04-25)
8-K (2024-03-22)
8-K (2024-01-31)
8-K (2024-01-29)
8-K (2023-12-21)
8-K (2023-12-01)
8-K (2023-11-09)
8-K (2023-10-20)
8-K (2023-09-13)
8-K (2023-08-10)
8-K (2023-08-04)
8-K (2023-06-09)
8-K (2023-06-02)
8-K (2023-05-31)
8-K (2023-05-11)
8-K (2023-04-13)
8-K (2023-03-15)
8-K (2023-03-13)
8-K (2023-01-20)
10-Q (2024-08-08)
10-Q (2024-05-09)
10-Q (2023-11-09)
10-Q (2023-08-10)
10-Q (2023-05-11)
10-K (2024-03-22)
10-K (2023-03-15)
Earnings Calls
Earnings Report 2022Q4
Earnings Report (2023-03-15)
Factset
Factset Business Description
Factset Street Account
Hookipa Pharma reports Q3 EPS ($0.17) vs FactSet ($0.21) [6 est, ($0.26)-(0.16)] ($0.50, 0.00) (2023-11-09T12:11:32Z)
Hookipa Pharma presents positive Biomarker and translational data on HB-200 monotherapy at SITC 2023 ($0.45, +0.02) (2023-11-03T16:05:21Z)
HOOKIPA Pharma presents additional preliminary Phase 2 data on HB-200 in combination with pembrolizumab as first-line treatment in patients with HPV16+ head and neck cancers at ESMO ($0.47, 0.00) (2023-10-22T15:18:57Z)
HOOKIPA Pharma announces publication of preclinical data of hepatitis B virus (HBV) therapeutic vaccine developed in collaboration with Gilead Sciences (GILD) ($0.52, 0.00) (2023-10-18T11:05:30Z)
HOOKIPA Pharma announces FDA clearance of IND application for HB-500 for treatment of human immunodeficiency virus ($0.52, 0.00) (2023-11-20T12:03:39Z)